311 related articles for article (PubMed ID: 21546498)
1. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
Gunnarsson R; Mansouri L; Isaksson A; Göransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R
Haematologica; 2011 Aug; 96(8):1161-9. PubMed ID: 21546498
[TBL] [Abstract][Full Text] [Related]
2. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.
Marincevic M; Cahill N; Gunnarsson R; Isaksson A; Mansouri M; Göransson H; Rasmussen M; Jansson M; Ryan F; Karlsson K; Adami HO; Davi F; Jurlander J; Juliusson G; Stamatopoulos K; Rosenquist R
Haematologica; 2010 Sep; 95(9):1519-25. PubMed ID: 20421269
[TBL] [Abstract][Full Text] [Related]
3. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
[TBL] [Abstract][Full Text] [Related]
4. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
5. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
7. Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
Schweighofer CD; Coombes KR; Majewski T; Barron LL; Lerner S; Sargent RL; O'Brien S; Ferrajoli A; Wierda WG; Czerniak BA; Medeiros LJ; Keating MJ; Abruzzo LV
J Mol Diagn; 2013 Mar; 15(2):196-209. PubMed ID: 23273604
[TBL] [Abstract][Full Text] [Related]
8. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
10. An Anomaly with Potential as a New Prognostic Marker in CLL with del(13q): Gain of 16p13.3.
Isik S; Gunden G; Gunduz E; Akay OM; Aslan A; Ozen H; Cilingir O; Erzurumluoglu Gokalp E; Kocagil S; Artan S; Gulbas Z; Durak Aras B
Cytogenet Genome Res; 2021; 161(10-11):479-487. PubMed ID: 34915466
[TBL] [Abstract][Full Text] [Related]
11. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
12. Genomic aberrations and survival in chronic lymphocytic leukemia.
Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
[TBL] [Abstract][Full Text] [Related]
13. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
Kröber A; Seiler T; Benner A; Bullinger L; Brückle E; Lichter P; Döhner H; Stilgenbauer S
Blood; 2002 Aug; 100(4):1410-6. PubMed ID: 12149225
[TBL] [Abstract][Full Text] [Related]
14. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
[TBL] [Abstract][Full Text] [Related]
15. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
Edelmann J; Holzmann K; Miller F; Winkler D; Bühler A; Zenz T; Bullinger L; Kühn MW; Gerhardinger A; Bloehdorn J; Radtke I; Su X; Ma J; Pounds S; Hallek M; Lichter P; Korbel J; Busch R; Mertens D; Downing JR; Stilgenbauer S; Döhner H
Blood; 2012 Dec; 120(24):4783-94. PubMed ID: 23047824
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia in a young population.
Alshemmari SH; Hamdah A; Pandita R; Kunhikrishnan A
Leuk Res; 2021 Nov; 110():106668. PubMed ID: 34492597
[TBL] [Abstract][Full Text] [Related]
17. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
[TBL] [Abstract][Full Text] [Related]
18. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.
Hagenkord JM; Monzon FA; Kash SF; Lilleberg S; Xie Q; Kant JA
J Mol Diagn; 2010 Mar; 12(2):184-96. PubMed ID: 20075210
[TBL] [Abstract][Full Text] [Related]
19. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.
Gunnarsson R; Isaksson A; Mansouri M; Göransson H; Jansson M; Cahill N; Rasmussen M; Staaf J; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Juliusson G; Rosenquist R
Leukemia; 2010 Jan; 24(1):211-5. PubMed ID: 19741724
[No Abstract] [Full Text] [Related]
20. Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: experience from India.
Amare PS; Gadage V; Jain H; Nikalje S; Manju S; Mittal N; Gujral S; Nair R
Indian J Cancer; 2013; 50(3):261-7. PubMed ID: 24061469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
